



01-25-02

A/BOXSEED

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37C F.R. §1.53(b))

Attorney Docket No. PC10970AGLK

First Named Inventor or Application Identifier Lee Harland

Title Novel Polypeptide

Express Mail Label No. EL912062320US

10701055106
U.S. PTO
01/23/02

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Specification [Total Pages 19]

3. Drawing(s) (35 U.S.C. 11.3) [Total sheets 2]

4. Oath or Declaration [Total pages 2]

a. Newly executed (original or copy)

b. Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

i. DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b, is
considered to be part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.

6. Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. Computer Readable Copy

b. Paper Copy (identical to computer copy)

c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & document(s))

9. 37 C.F.R. §3.73(b) Statement Power of Attorney
(when there is an assignee)

10. English Translation Document (if applicable)

11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. *Small Entity Statement(s) Statement filed in prior application,
Status still proper and desired
(PTO/SB/09-12)

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

14. Other: Priority Claim
GB 0101739.1 Filed on 01/23/2001
US 60/267,341 Filed on 02/08/2001

**NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).*

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation Divisional Continuation-in-part (CIP) of prior application No: _____ / _____

Prior application information: Examiner _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)			<input checked="" type="checkbox"/> Correspondence address below
Name	Gregg C. Benson			
Address	Pfizer Inc.			
Address	Patent Department, MS 4159, Eastern Point Road			
City	Groton	State	CT	Zip Code 06340
Country	United States Of America	Telephone	1-(860)-441-4901	Fax 1-(860)-441-5221
NAME (Print/type)	Gabriel L. Kleiman		Registration No. (Attorney/Agent)	40,681
Signature	Substantive		Date	1/23/2002

UTILITY TRANSMITTAL PTO SB 05, 9/99, (1/1)

EXPRESS MAIL NO. EL912062320US

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 2001.

Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$3,450.00)

Complete if Known	
Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Lee Harland
Examiner Name	To be assigned
Group/Art Unit	To be assigned
Attorney Docket No.	PC10970AGLK

METHOD OF PAYMENT (check one)

1. The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc.

Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.16 and 1.17. Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. Payment Enclosed:

Check Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES


Large Entity	Small Entity	Fee Description	Fee Paid		
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					
SUBTOTAL (2) (\$)		2710.00			
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3) (\$)		0			

SUBMITTED BY

Complete (if Applicable)

Type or Printed Name Gabriel L. Kleiman

Reg. Number 40,681

Signature 

Deposit Account 16-1445

User ID

EXPRESS MAIL NO. EL9120232015

Patent
Attorney Docket No. PC10970AGLK

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to:
Box Patent Application, Commissioner For Patents, Washington, D.C. 20231 on this 23rd day of January, 2002.

By

Janice M. Denison
(Signature of person mailing)
Janice M. Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Lee Harland**

APPLICATION NO.: **To be assigned**

: Examiner: **To be assigned**

FILING DATE: **Herewith**

: Group Art Unit: **To be assigned**

TITLE: **Novel Polypeptide**

:

Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to
the written sequence listing.

Date:

1/23/2002

Respectfully submitted,

Gabriel L. Kleiman

Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,681

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041

EXPRESS MAIL NO. *EL912012320US*

10055406 042306